Chapter 25
Immunosuppressive Therapy to Counter Cardiac Allograft Vasculopathy
Carl V. Leier,
Carl V. Leier
Search for more papers by this authorCarl V. Leier,
Carl V. Leier
Search for more papers by this authorBook Editor(s):Ronald Ross Watson,
Douglas F. Larson,
Ronald Ross Watson
Department of Nutritional Sciences, The University of Arizona; and Sarver Heart Center, College of Medicine, The University of Arizona
Division of Health Promotion Sciences, Mel and Enid Zuckerman Arizona College of Public Health, The University of Arizona Tucson, AZ USA
Search for more papers by this authorDouglas F. Larson
Sarver Heart Center College of Medicine The University of Arizona Tucson, AZ USA
Search for more papers by this authorFirst published: 30 August 2007
Summary
This chapter contains section titled:
-
Overview
-
Cardiac allograft vasculopathy: general concepts
-
Cardiac allograft vasculopathy: management approach
-
Closing comments
-
References
References
- O'Neill BJ Pflugfelder PW Singh NR Menkis AH McKenzie FN Kostuk W.J. Frequency of angiographic detection and quantitative assessment of coronary arterial disease one and three years after cardiac transplantation. Am J Cardiol 1989; 63: 1221–6.
- Gao, SZ, Schroeder, JS, Hunt, SA, Billingham, ME, Valentine HA Stinson E.B. Acute myocardial infarction in cardiac transplant recipients. Am J Med 1989; 64: 1093–7.
- Gao SZ Hunt SA Schroeder JS Alderman EL Hill IR Stinson E.B. Early development of accelerated graft coronary artery disease: risk factors and course. J Am Coll Cardiol 1996; 28: 673–9.
- Tuzcu EM De Franco AC Goormastic M et al. Dichoto-mous pattern of coronary atherosclerosis 1 to 9 years after transplantation: insights from systematic intravascular ultrasound imaging. J Am Coll Cardiol 1996; 27: 839–46.
- Hornick P Smith J Pomerance A et al. Influence of acute rejection episodes, HLA matching, and donor/ recipient phenotype on the development of 'early' transplant-associated coronary artery disease. Circulation 1997; 96 (suppl II): II148–53.
- Mazur W Bitar JN Young J. et al. Progressive deterioration of coronary flow reserve after transplantation. Am Heart J 1998; 136: 504–9.
- Yamani MH Tuzcu EM Starling R. et al. Computerized scoring of histopathology for predicting coronary vas-culopathy, validated by intravascular ultrasound. J Heart Lung Transplant 2002; 21: 850–9.
- Kushwaha SS Narula J Narula N et al. Pattern of changes over time in myocardial blood flow and microvascular dilator capacity in patients with normally functioning cardiac allografts. Am J Cardiol 1998; 82: 1377–81.
- John R, Rajasinghe HA, Itescu S et al. Factors affecting long-term survival (10 years) after cardiac transplantation in the cyclosporine era. J Am Coll Cardiol 2001; 37: 189–94.
- Potluri SP Mehra MR Uber PA Park MH Scott RL Ventura H.O. Relationship among epicardial coronary disease, tissue myocardial perfusion, and survival in Heart transplantation. J Heart Lung Transplant 2005; 24: 1019–25.
- Olsen SL Wagoner LE Hammond E. et al. Vascular rejection in Heart transplantation: clinical correlation, treatment options, and future considerations. J Heart Lung Transplant 1993; 12: S135–42.
- Costanzo MR Naftel DC Pritzker M. et al, and the Cardiac Transplant Research Database. Heart transplant coronary artery disease detected by coronary angiogra-phy: a multiinstitutional study of preoperative donor and recipient risk factors. J Heart Lung Transplant 1998; 17: 744–53.
- Mainigi SK Goldberg LR Sasseen BM See VY Jr, Wilen-sky R.L. Relative contributions of intimal hyperplasia and vascular remodeling in early cardiac transplant-mediated coronary artery disease. Am J Cardiol 2003; 91: 293–6.
- Tsutsui H Ziada KM Schoenhagen P et al. Lumen loss in transplant coronary disease is a biphasic process involving early intimal thickening and late constrictive remodeling. Circulation 2001; 104: 653–7.
- Muehling OM, Wilke NM, Panse Petal. Reduced myocar-dial perfusion reserve and transmural perfusion gradient in Heart transplant arteriopathy assessed by magnetic resonance imaging. J Am Coll Cardiol 2003; 42: 1054–60.
- Haddad M Pflugfelder PW Guiraudon C et al. Angio-graphic, pathologic, and clinical relationships in coronary artery disease in cardiac allografts. J Heart Lung Transplant 2005; 24: 1218–25.
- Reed EF Demetris AJ Hammond E et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 2006; 25: 153–9.
- Micheals PJ Espejo ML Kobashigawa J et al. Humoral rejection in cardiac transplantation: risk factors, hemody-namic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003; 22: 58–69.
- Cherry R Nielsen H Reed E Reemtsma K Suciu-Foca N Marboe C.C. Vascular (humoral) rejection in human allograft biopsies: relation to circulating anti-HLA antibodies. J Heart Lung Transplant 1992; 11: 24–30.
- Rose EA Pepino P Barr M. et al. Relation of HLA antibodies and graft atherosclerosis in human cardiac allo-graft recipients. J Heart Lung Transplant 1992; 11: S120–3.
- Gullestad L Simonsen S Ueland T et al. Possible role of proinflammatory cytokines in Heart allograft coronary artery disease. Am J Cardiol 1999; 84: 999–1003.
- Hognestad A Endresen K Wergeland R et al. Plasma C-reactive protein as a marker of cardiac allograft vascu-lopathy in Heart transplant recipients. J Am Coll Cardiol 2003; 42: 477–82.
- Hosenpud JD Everett JP Morris TE Mauck KA Shipley GD Wagner C.R. Cardiac allograft vasculopathy. Association with cell-mediated but not humoral alloimmu-nity to donor specific vascular endothelium. Circulation 1995; 92: 205–11.
- Fredrich R Toyoda M Czer L. et al. The clinical significance of antibodies to human vascular endothe-lial cells after cardiac transplantation. Transplantation 1999; 67: 385–91.
- Joyce DL Southard RE Torre-Amione G Noon GP Land GA Loebe M. Impact of left ventricular assist device (LVAD)-mediated humoral sensitization on post-transplant outcomes. J Heart Lung Transplant 2005; 24: 2054–9.
- Cooke GE Eaton GM Whitby G et al. Plasma athero-genic factors in congestive Heart failure and posttrans-plant (Heart) patients. J Am Coll Cardiol 2000; 36: 509–16.
- Kemna MS Valantine HA Hunt SA Schroeder JS Chen Y-DI Reaven G.M. Metabolic risk factors for atherosclerosis in Heart transplant recipients. Am Heart J 1994; 128: 68–72.
- Kapadia SR Nissen SE Ziada K. et al. Impact of lipid abnormalities in development and progression of transplant coronary disease: a serial intravascular ultrasound study. J Am Coll Cardiol 2001; 38: 206–13.
- Kato T Chan MCY Gao S-Z et al. Glucose intolerance, as reflected by hemoglobin A1c level, is associated with the incidence and severity of transplant coronary disease. J Am Coll Cardiol 2004; 43: 1034–41.
- Senechal M Lemieux I Beucler I et al. Features of the metabolic syndrome of “hypertriglyceridemic waist” and transplant coronary disease. J Heart Lung Transplant 2005; 24: 819–26.
- Stoica SC Cafferty F Pauriah M et al. The cumulative effect of acute rejection on development of cardiac allograft vasculopathy. J Heart Lung Transplant 2006; 25: 420–5.
- Benza RL Grenett HE Bourge R. et al. Gene polymorphisms for plasminogen activator inhibitor-1/tissue plas-minogen activator and development of allograft coronary artery disease. Circulation 1998; 98: 2248–54.
- Valentine H Rickenbacker P Kemna M et al. Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease. Circulation 2001; 103: 2144–52.
- Lindenfeld J Miller GG Shakar S. et al. Drug therapy in the Heart transplant recipient. Circulation. Part I: 2004; 110: 3734–40. Circulation. Part II: 2004; 110: 3858–65.
- Ferraro P Carrier M White M Pelletier GB Pelletier L.C. Antithymocyte globulin and methotrexate therapy of se-vere or persistent cardiac allograft rejection. Ann Thorac Surg 1995; 60: 372–6.
- Partanen J Nieminen MS Krogerus L Harjula ALJ Mattila S. Heart transplant rejection treated with plasmapheresis. J Heart Lung Transplant 1992; 11: 301–5.
- Ratkovec RM Hammond EH O'Connell J. et al. Outcome of cardiac transplant recipients with a positive donor-specific crossmatch—preliminary results with plasmapheresis. Transplantation 1992; 54: 651–5.
- Kobashigawa J.A. Statins as immunosuppressive agents. Liver Transplant 2001; 7: 559–61.
- Kobashigawa JA Katznelson S Laks H et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621–7.
- Kobashigawa JA Moriguchi JD Laks H et al. Ten-year follow-up of a randomized trial of pravastatin in Heart transplant patients. J Heart Lung Transplant 2005; 24: 1736–40.
- Wenke K Meiser B Thiery J et al. Simvastatin reduces graft vessel disease and mortality after Heart transplantation—a four year randomized trial. Circulation 1997; 96: 1398–402.
- Mehra MR Uber PA Vivekananthan K et al. Comparative beneficial effects of simvastatin and pravastatin in cardiac allograft rejection and survival. J Am Coll Cardiol 2002; 40: 1609–14.
- Weis M Pehlivanli S Meiser BM von Scheidt W. Simvas-tatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after Heart transplantation. J Am Coll Cardiol 2001; 38: 814–8.
- Cotts WG Johnson M.R. The challenge of rejection and cardiac allograft vasculopathy. Heart Failure Rev 2001; 6: 227–40.
- Mehra MR Ventura HO Smart FW Stapleton D.D. Impact of converting enzyme inhibitors and calcium entry blockers in cardiac allograft vasculopathy. J Heart Lung Transplant 1995; 14: S246–9.
- Erinc K Yamani MH Starling R. et al. The effect of combined angiotensin-converting enzyme inhibition and calcium antagonism on cardiac allograft vasculopa-thy validated by intravascular ultrasound. J Heart Lung Transplant 2005; 24: 1033–8.
- Kobashigawa JA Meiser B.M. Review of major clinical trials with mycophenolate mofetil in cardiac transplantation. Transplantation 2005; 80: S235–43.
- Kobashigawa J Miller J Renlund D et al. A randomized active-controlled trial of mycophenolate mofetil in Heart transplant recipients. Transplantation 1998; 66: 507–15.
- Pethig K Heublein B Wahlers T Dannenberg O Oppelt P Haverich A. Mycophenolate mofetil for secondary prevention of cardiac allograft vasculopathy: influence on inflammation and progression of intimal hyperplasia. J Heart Lung Transplant 2004; 23: 61–6.
- El-Sayed O Magorien RD Orsini A Ferketich AK Leier C.V. Advancing immunosuppression therapy to counter the progression of cardiac allograft vasculopathy. J Cardiac Failure 2005; 11: 137–41.
- Kaczmarek I Ertl B Schmauss D et al. Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil. J Heart Lung Transplant 2006; 25: 550–6.
- Rose ML Smith J Dureau G Keogh A Kobashigawa J. Mycophenolate mofetil decreases antibody production after cardiac transplantation. J Heart Lung Transplant 2002; 21: 282–5.
- Ruygrok PN Webber B Faddy S Muller DW Keogh A. Angiographic regression of cardiac vasculopathy after introducing sirolimus immunosuppression. J Heart Lung Transplant 2003; 22: 1276–9.
- Keogh A Richardson M Ruygrok P et al. Sirolimus in de novo Heart transplant recipients reduces acute rejection and prevents coronary disease at 2 years: a randomized clinical trial. Circulation 2004; 110: 2694–700.
- Mancini D Pinney S Burkhoff D et al. Use of rapamycin slows progression of cardiac transplantation vasculopa-thy. Circulation 2003; 108: 48–53.
- Eisen HJ Tuzcu EM Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopa-thy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847–58.
- Klaus V Koning A Spes C et al. Cyclosporine versus tacrolimus (FK 506) for prevention of cardiac allograft vasculopathy. Am J Cardiol 2000; 85: 266–9.
- Kobashigawa JA Patel J Furukawa H et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in Heart transplant patients. J Heart Lung Transplant 2006; 25: 434–9.
- Ballester M Obrador D Carrio I et al. Reversal of rejection-induced coronary vasculitis detected early after Hearttransplantationwithincreasedimmunosuppres-sion. J Heart Lung Transplant 1989; 8: 413–7.
- Lamich R Ballester M Marti V et al. Efficacy of augmented immunosuppressive therapy for early vascu-lopathy in Heart transplantation. J Am Coll Cardiol 1998; 32: 413–9.
- Pelletier MP Coady MA Macha M Oyer PE Robbins R.C. Coronary atherosclerosis in cardiac transplant patients treated with total lymphoid irradiation. J Heart Lung Transplant 2003; 22: 124–9.
- Hershberger RE Starling RC Eisen H. et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005; 352: 2705–13.
- Han WR Zhan Y Murray-Segal LJ Brady JL Lew AM Mottram P.L. Prolonged allograft survival in anti-CD4 antibody transgenic mice: lack of residual helper T cells compared with other CD4-deficient mice. Transplantation 2000; 70: 168–74.
- Szeto WY Krasinskas AM Kreisel D Krupnick AS Popma SH Rosengard B.R. Depletion of recipient CD4+ but not CD8+ T lymphocytes prevents the development of cardiac allograft vasculopathy. Transplantation 2002; 73: 1116–22.
- Wang CY Mazer SP Minamoto K et al. Suppression of murine cardiac allograft arteriopathy by long-term blockade of CD40-CD154 interactions. Circulation 2002; 105: 1609–14.
- Uehara S Chase CM Colvin RB Russell PS Madsen J.C. Further evidence that NK cells may contribute to the development of cardiac allograft vasculopathy. Transplant Proc 2005; 37: 70–1.
- Ternstrom L Jeppsson A Ricksen A Nilsson F. Tumor necrosis factor gene polymorphism and cardiac allograft vasculopathy. J Heart Lung Transplant 2005; 24: 433–8.
- Koglin J Glysing-Jensen T Gadiraju S Russell M.E. Attenuated cardiac allograft vasculopathy in mice with targeted deletion of the transcription factor STAT4. Circulation 2000; 101: 1034–9.
